Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Trisciuoglio D, Iuliano A, Del Bufalo D, Di Bernardo D, Melisi D, Draetta GF, Ciliberto G, Carugo A, Cardone L.
Mottini C, et al. Among authors: cardone l.
Cancer Res. 2019 Nov 1;79(21):5612-5625. doi: 10.1158/0008-5472.CAN-19-0187. Epub 2019 Sep 5.
Cancer Res. 2019.
PMID: 31492820